Altimmune to Present at Upcoming Virtual Investor Conferences
Fireside chat recording available to conference participants
The sessions will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
Altimmune, Investor Relations
Source: Altimmune, Inc.